Table 4.
Univariate Analysis of Predictors of Pathologic Response and Tumor Thickness at TNI*.
| Pathologic Response | Tumor Thickness at TNI | |||||||
|---|---|---|---|---|---|---|---|---|
| Complete (N=14) | Major (N=84) | Minor (N=73) | P | <0.5 mm (N=35) | ≤0.5 mm and <5 mm (N=97) | ≥5 mm (N=39) | P | |
| Male sex | 7 | 41 | 40 | .75 | 20 | 44 | 24 | .18 |
| Median age (range), yr | 60 (36-71) | 60 (26-83) | 60 (34-85) | .72 | 61 (26-85) | 60 (30-83) | 58 (34-83) | .48 |
| Synchronous CLM | 8 | 54 | 44 | .81 | 24 | 60 | 22 | .56 |
| Rectal primary | 6 | 36 | 36 | .70 | 16 | 40 | 22 | .28 |
| Positive lymphnode primary | 6 | 50 | 43 | .49 | 17 | 60 | 22 | .39 |
| Median CEA (range), ng/mL | 2.5 (1-50) | 4 (0-1640) | 5 (0-963) | .93 | 2.7 (0-113) | 4 (0-1640) | 6 (0-859) | .22 |
| Median duration of preoperative chemotherapy (range), months | 3 (2-12) | 3 (0-10) | 3 (0-11) | .68 | 3 (0-12) | 4 (0-11) | 3 (0-6.5) | .08 |
| Chemotherapy regimens† | ||||||||
| Oxaliplatin±bevacizumab | 10 | 56 | 40 | .31 | 23 | 68 | 15 | .018 |
| Irinotecan±bevacizumab | 2 | 22 | 23 | 7 | 24 | 16 | ||
| Bevacizumab† | ||||||||
| Yes | 5 | 41 | 25 | .3 | 15 | 48 | 8 | .036 |
| No | 7 | 37 | 38 | 15 | 44 | 23 | ||
| Number of CLM, median (range) | 2 (1-7) | 2 (1-13) | 2 (1-13) | .84 | 2 (1-13) | 2 (1-13) | 2 (1-11) | .996 |
| Median diameter of the largest CLM (range), cm | 1.1 (0.3-4.5) | 2.5 (0.5-9.5) | 3 (0.3-13) | .002 | 2 (0.3-8) | 3 (0.3-9.5) | 3.5 (1-13) | <.001 |
| Tumor thickness at TNI <0.5 mm | 14 (100) | 20 (23.8) | 1 (1.4) | <.001 | - | - | - | - |
| Complete pathologic response | - | - | - | - | 14 (40) | 0 | 0 | <.001 |
Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; TNI, tumor–normal tissue interface.
*
Values in table are number of patients unless otherwise indicated.
†
Patients receiving multiple regimens of preoperative chemotherapy (n=13), only fluropyrimidines (n=4) and cetuximab (n=1) were excluded from this analysis, finally including 153 patients.